Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?Zacks Investment Research • 10/07/20
BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH PatientsGlobeNewsWire • 09/30/20
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National StockpileGlobeNewsWire • 09/03/20
NIAID Awards BioCryst New $44 Million Contract to Advance Development of GalidesivirGlobeNewsWire • 08/31/20
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?Zacks Investment Research • 08/11/20
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/06/20
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 08/06/20
BioCryst Pharmaceuticals: Important Catalysts Could Drive Additional Upside In 2H 2020Seeking Alpha • 07/20/20
BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be WrongThe Motley Fool • 07/07/20
BofA Securities Has 5 Stocks to Buy Under $10 With Massive Upside Potential24/7 Wall Street • 06/13/20